Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pathogenic skin bacteria represent a broad array of bacterial species that can infect the skin, leading to conditions ranging from minor superficial infections such as impetigo and folliculitis to severe deep infections such as cellulitis, abscesses, and necrotizing fasciitis. The most common pathogenic skin bacteria are Staphylococcus aureus (including MRSA) and Streptococcus pyogenes, but others such as Corynebacterium minutissimum, Pseudomonas aeruginosa, and mycobacteria can also cause skin disease. These organisms may be part of the normal microbiota but can become pathogenic when barriers are breached or the immune system is compromised. Treatment depends on the causative organism and resistance profile, and antibiotic resistance is an increasing concern[1][2][3][4][5][6].
Inhibition of cell wall synthesis (e.g., beta-lactams); Inhibition of protein synthesis (e.g., tetracyclines, clindamycin); Disruption of nucleic acid synthesis (e.g., fluoroquinolones); Disruption of bacterial membranes (e.g., polymyxins)
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pathogenic skin bacterium.